Consensus $238.83The company said, “For the full year of 2025, the Company increased its revenue guidance from $235.0 million to $242.0 million up to $236.0 million to $242.0 million, representing growth of 15% to 18% over 2024 revenue. The Company reiterated annual set deployment to be $15.0 million and reiterated $15.0 million to $17.0 million of adjusted EBITDA for the full year of 2025.”
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KIDS:
- OrthoPediatrics Highlights Financial Insights and Innovations
- OrthoPediatrics price target lowered to $38 from $44 at BTIG
- OrthoPediatrics price target lowered to $24 from $26 at Truist
- OrthoPediatrics: Strategic Expansion and Risk Mitigation Justify Buy Rating
- OrthoPediatrics announces U.S. launch of VerteGlide Spinal Growth Guidance